

Michael D Ezekowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8915501/publications.pdf>

Version: 2024-02-01

127
papers

38,668
citations

36691

53
h-index

20023

121
g-index

130
all docs

130
docs citations

130
times ranked

22494
citing authors

#	ARTICLE	IF	CITATIONS
1	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	1.8	8
2	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	1.8	18
3	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
4	Drug Interactions Affecting Antiarrhythmic Drug Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, 101161CIRCEP121007955.	2.1	6
5	Drug Interactions Affecting Oral Anticoagulant Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, .	2.1	13
6	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471.	0.9	7
7	Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, , 1.	0.6	10
8	Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 152, 69-77.	0.7	3
9	The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. <i>Trials</i> , 2021, 22, 603.	0.7	4
10	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. <i>American Heart Journal</i> , 2020, 219, 21-30.	1.2	8
11	Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. <i>American Heart Journal</i> , 2020, 223, 65-71.	1.2	22
12	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 4037-4046.	1.0	90
13	Differences in Thromboembolic Complications Between Paroxysmal and Persistent Atrial Fibrillation Patients Following Electrical Cardioversion (From the ENSURE-AF Study). <i>American Journal of Cardiology</i> , 2020, 131, 27-32.	0.7	10
14	Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	2.8	5
15	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e018984.	1.6	37
16	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007775.	2.1	6
17	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020, 41, 2848-2859.	1.0	25
18	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	1.9	14

#	ARTICLE	IF	CITATIONS
19	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. PLoS ONE, 2020, 15, e0226259.	1.1	1
20	Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VerT Trial. TH Open, 2020, 04, e20-e32.	0.7	29
21	Left Ventricular Thrombi. Journal of the American College of Cardiology, 2020, 75, 1686-1688.	1.2	2
22	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart, 2019, 105, heartjnl-2018-313642.	1.2	22
23	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	3.0	10
24	Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. Europace, 2019, 21, 1633-1638.	0.7	15
25	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation, 2019, 140, e125-e151.	1.6	1,925
26	2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Heart Rhythm, 2019, 16, e66-e93.	0.3	282
27	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 74, 104-132.	1.2	1,458
28	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 2019, 213, 81-90.	1.2	10
29	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005358.	0.9	59
30	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Europace, 2019, 21, 1023-1030.	0.7	5
31	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	10
32	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial. Journal of the American Heart Association, 2019, 8, e010107.	1.6	17
33	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation, 2018, 138, 889-897.	1.6	23
34	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). Journal of the American Heart Association, 2018, 7, .	1.6	143
35	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	92
36	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time: A RE-LY trial analysis. American Heart Journal, 2018, 198, 169-177.	1.2	14

#	ARTICLE	IF	CITATIONS
37	Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1878-1889.	1.1	18
38	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation—the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) study. <i>Europace</i> , 2018, 20, 253-262.	0.7	11
39	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54.	3.0	77
40	Disease understanding in patients newly diagnosed with atrial fibrillation. <i>Heart</i> , 2018, 104, 494-501.	1.2	25
41	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 435-439.	1.0	9
42	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	1.2	56
43	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	1.2	78
44	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	1.2	42
45	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017, 194, 132-140.	1.2	161
46	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017, 19, 1630-1636.	0.7	16
47	The impact of IMPACT-AF. <i>Lancet, The</i> , 2017, 390, 1717-1718.	6.3	4
48	Patients With Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1377-1379.	1.3	1
49	Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 682-690.	2.4	47
50	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. <i>American Heart Journal</i> , 2016, 179, 59-68.	1.2	32
51	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016, 387, 2302-2311.	6.3	389
52	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
53	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2016, 134, 589-598.	1.6	140
54	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , 2016, 388, 1161-1169.	6.3	216

#	ARTICLE	IF	CITATIONS
55	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	0.6	21
56	Cardioversion of Atrial Fibrillation in <sc>ENGAGE AFâ€TIMI</sc> 48. <i>Clinical Cardiology</i> , 2016, 39, 345-346.	0.7	53
57	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
58	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, 1117-1123.e2.	0.6	14
59	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	1.2	34
60	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	0.8	29
61	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	0.7	19
62	Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. <i>International Journal of Cardiology</i> , 2016, 202, 578-585.	0.8	34
63	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	1.2	197
64	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 796-803.	1.6	90
65	Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. <i>International Journal of Cardiology</i> , 2015, 196, 127-131.	0.8	74
66	A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400Âmg twice daily for 12Âweeks on atrial fibrillation burden in subjects with permanent pacemakers. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 42, 69-76.	0.6	15
67	A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. <i>American Heart Journal</i> , 2015, 169, 597-604.e5.	1.2	31
68	Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1204-1209.	0.7	54
69	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 1151-1160.	1.2	99
70	Response to Letter Regarding Article, â€œManagement and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarinâ€¸. <i>Circulation</i> , 2014, 130, e95.	1.6	0
71	Novel Anticoagulants Eliminate the Need for Left Atrial Appendage Exclusion Devices. <i>Circulation</i> , 2014, 130, 1505-1514.	1.6	6
72	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, e199-267.	1.6	3,471

#	ARTICLE	IF	CITATIONS
73	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 321-328.	1.2	733
74	Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2014, 167, 601-609.e1.	1.2	135
75	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , 2014, 113, 669-675.	0.7	14
76	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	1.6	346
77	Rationale and design of the eXplore the efficacy and safety of once-daily oral rivaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTtrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. <i>American Heart Journal</i> , 2014, 167, 646-652.	1.2	25
78	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2014, 383, 955-962.	6.3	3,942
79	Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 168, 487-494.	1.2	107
80	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014, 100, 1193-1200.	1.2	47
81	Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulantsâ€”translating clinical trial data into practice. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 40, 261-268.	0.6	2
82	Abstract 19504: Factors Predicting Sinus Rhythm in Patients Cardioverted in the X-VERT Study. <i>Circulation</i> , 2014, 130, .	1.6	0
83	Dabigatran Versus Warfarin. <i>Stroke</i> , 2013, 44, 1891-1896.	1.0	292
84	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
85	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013, 15, 1540-1556.	0.7	125
86	Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. <i>Circulation</i> , 2013, 127, 1404-1412.	1.6	222
87	Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 246-252.e5.	2.4	67
88	Response to Letter Regarding Article, â€œCardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudyâ€• <i>Circulation</i> , 2013, 127, e278-9.	1.6	1
89	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 2192-2201.	1.6	268
90	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the REâ€•LY trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1053-1061.	2.9	82

#	ARTICLE	IF	CITATIONS
91	Response to Letter Regarding Article, "Atrial Fibrillation: Outpatient Presentation and Management". <i>Circulation</i> , 2012, 125, .	1.6	0
92	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. <i>Circulation</i> , 2012, 125, 669-676.	1.6	348
93	Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 1605-1616.	1.6	346
94	Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. <i>Stroke</i> , 2012, 43, 1511-1517.	1.0	385
95	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. <i>Circulation</i> , 2012, 126, 343-348.	1.6	494
96	A randomized trial of budioparone in paroxysmal atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2012, 34, 1-9.	0.6	24
97	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. <i>Blood</i> , 2012, 120, 19-19.	0.6	7
98	Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -. <i>Circulation Journal</i> , 2011, 75, 800-805.	0.7	107
99	Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 131-136.	1.6	446
100	Dabigatran in atrial fibrillation: pharmacology and clinical trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2011, 32, 173-180.	0.6	7
101	Atrial Fibrillation. <i>Circulation</i> , 2011, 124, 95-99.	1.6	10
102	Response to Letter by Willey. <i>Stroke</i> , 2010, 41, .	1.0	0
103	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology</i> , The, 2010, 9, 1157-1163.	4.9	399
104	Dabigatran and Warfarin in Vitamin K Antagonist "Naive and "Experienced Cohorts With Atrial Fibrillation. <i>Circulation</i> , 2010, 122, 2246-2253.	1.6	158
105	The Evolving Field of Stroke Prevention in Patients With Atrial Fibrillation. <i>Stroke</i> , 2010, 41, S17-S20.	1.0	15
106	Principles of Anticoagulation and New Therapeutic Agents in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2010, 2, 479-492.	0.7	1
107	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet</i> , The, 2010, 376, 975-983.	6.3	913
108	Newly Identified Events in the RE-LY Trial. <i>New England Journal of Medicine</i> , 2010, 363, 1875-1876.	13.9	652

#	ARTICLE	IF	CITATIONS
109	The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation. <i>Circulation</i> , 2009, 120, 1029-1035.	1.6	79
110	Response to Letter Regarding Article, "Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial" <i>Circulation</i> , 2009, 120, .	1.6	0
111	Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. <i>American Heart Journal</i> , 2009, 157, 805-810.e2.	1.2	298
112	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	13.9	9,839
113	Diastolic dysfunction and atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2008, 22, 111-118.	0.6	46
114	Advancement in antithrombotics for stroke prevention in atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2008, 22, 129-137.	0.6	21
115	New developments in anticoagulation for atrial fibrillation. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 388-397.	0.4	11
116	Chronic Antithrombotic Therapy in Post-Myocardial Infarction Patients. <i>Cardiology Clinics</i> , 2008, 26, 277-288.	0.9	5
117	The Primary and Secondary Prevention of Coronary Artery Disease. <i>Chest</i> , 2008, 133, 776S-814S.	0.4	234
118	Maintaining Sinus Rhythm " Making Treatment Better Than the Disease. <i>New England Journal of Medicine</i> , 2007, 357, 1039-1041.	13.9	11
119	Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study). <i>American Journal of Cardiology</i> , 2007, 100, 1419-1426.	0.7	389
120	Amiodarone versus Sotalol for Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2005, 352, 1861-1872.	13.9	739
121	Anticoagulation Interruptus. <i>Circulation</i> , 2004, 110, 1518-1519.	1.6	10
122	Antithrombotic Therapy for Coronary Artery Disease. <i>Chest</i> , 2004, 126, 513S-548S.	0.4	196
123	Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey. <i>Clinical Therapeutics</i> , 2003, 25, 1750-1764.	1.1	104
124	Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction. <i>Circulation</i> , 2002, 105, 557-563.	1.6	212
125	Enhanced Monocyte Tissue Factor Response After Experimental Balloon Angioplasty in Hypercholesterolemic Rabbit: Inhibition With Dietary L-Arginine. <i>Circulation</i> , 1998, 98, 1776-1782.	1.6	41
126	Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis. <i>Circulation</i> , 1996, 93, 1913-1918.	1.6	59

#	ARTICLE	IF	CITATIONS
127	Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation. New England Journal of Medicine, 1992, 327, 1406-1412.	13.9	1,252